Market Research NewsNews

Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market by Top Manufacturers – Hoffman-La Roche Ltd., Johnson & Johnson, Bayer AG, Eli Lilly and Company, Amgen Inc., Novartis AG

Non-Hodgkin’s Lymphoma (NHL), has been expected to reach a new landscape in the forecast period due to the constant innovation and improvements on finding a viable drug to battle this disease. Due to the inability of major pharmaceuticals companies having a viable solution to it, the cost of treatment is very high and hence, the market is expected to soar higher in the forecast period of 2018-2025.

Get A Free Sample Report Now @

Major Players:

Hoffman-La Roche Ltd., Johnson & Johnson, Bayer AG, Eli Lilly and Company, Amgen Inc., Novartis AG, Bristol-Myers-Squibb, Gilead, Kite Pharma. Inc., GlaxoSmithKline plc., Celgene Corporation, Merck & Co., AstraZeneca, Pharmacyclics LLC, Nordic Nanovector ASA, Accredo Health Group Inc., Baxter, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Rescue Therapeutics Inc., 4SC AG, Agios Inc., Aileron Therapeutics Inc., Allinky Biopharma SL, Immune Design, are few of the major competitors currently dominating the market.

Competitive Analysis: 

Extensive R&D currently being conducted throughout the major pharmaceutical firms finding a treatment for Non-Hodgkin’s Lymphoma, but due to the high amount of R&D cost, it is proving to be a major hurdle in trying to find a viable solution and treatment.

Rise in sales of vehicles has also meant in the rise of road accidents worldwide. This has induced the automotive industry to innovate and develop automotive safety systems which include the Night Vision System and Driver Monitoring System. These systems play an important role in lessening the instances of road accidents.

Key Developments in the Market:

  • In August 2017,Gilead Sciences, Inc. and Kite Pharma, Inc. entered into a definitive agreement in August,2017 where the drug developed by Kite Pharma, Inc. currently under review by the US FDA, and is set to be one of the first drugs to be marketed for Non-Hodgkin’s Lymphoma
  • In November 2017,US FDA approved a drug called Calquence by AstraZeneca, plc and will hit the market for an aggressive form of Non-Hodgkin’s Lymphoma in adults

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Technological Writers, and Investors among others.

Supply Side: Product Managers, Marketing Managers, Distributors, Market Intelligence committees, Regulatory Authorities, Medical Institutes


  • Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report.
  • Customer’s Satisfaction: Our expert team will assist with all your research needs and customize the report.
  • Inimitable Expertise: Analysts will provide deep insights about the reports
  • Assured Quality: We focus on the quality and accuracy of the report
  • Technically acclaimed Analysts with complete industry know how Robust research methodology followed by our publishers to arrive at market estimates, Focus on technology trends, Extensive repository of market research reports to meet our client’s needs.
  • Based on extensive research, we provide clear view of real market scenario and help clients with making informed business decisions

Major Topics Covered in this Report:

Study Coverage

Executive Summary

Market Size by Manufacturers

Market Size by Type

Market Size by Application

Manufacturers Profiles

Production Forecasts

Consumption Forecast

Upstream, Industry Chain and Downstream Customers Analysis

Opportunities & Challenges, Threat and Affecting Factors

Key Findings


Request Complete TOC Of this Report @

Market Segmentation:

  • By treatment, all of the segments related to various treatments available in the market are set to witness worldwide growth due to the increasing cancer cases and no particular viable proven drug in the market. Global lymphoma treatment is set to witness healthy growth in all treatment segments.
  • By Cell Type
    • B-Cell Lymphomas
    • T-Cell Lymphomas
  • By geography, North America has been dominating the Non-Hodgkin’s Lymphoma treatment market due to its frequency of cancer cases, and it is set to continue that trend for the foreseeable future, followed by the APAC region of the world where it has developed better healthcare services and infrastructure.

Market Definition: 

Non-Hodgkin’s Lymphoma is a type of cancer that attacks the lymphoma tic cells that are present in our immune system and fights off infection and diseases. It is commonly found in both adults and children, and these type of cancerous cells can be found anywhere throughout the body, as the lymphoma tic cells are spread throughout the body.

Reasons to Purchase this Report

  • This report offers various market viewpoints that would help in progressing further
  • This report offers up the various avenues for the treatment of NHL, and which segment would progress the furthest during the forecast period of 2018-2023
  • Extensive market research analysis conducted to properly identify the key drivers and restraints

To know more please Request an Analyst Call or can drop down your inquiry… @

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us-

Data Bridge Market Research

US: +1-888-387-2818





Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *